Compare · DNA vs RVMD
DNA vs RVMD
Side-by-side comparison of Ginkgo Bioworks Holdings Inc. (DNA) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNA and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $42.84B, about 65.0x DNA ($659.5M).
- Over the past year, DNA is down 19.5% and RVMD is up 344.9% - RVMD leads by 364.3 points.
- RVMD has been more active in the news (19 items in the past 4 weeks vs 4 for DNA).
- RVMD has more recent analyst coverage (25 ratings vs 18 for DNA).
- Company
- Ginkgo Bioworks Holdings Inc.
- Revolution Medicines Inc.
- Price
- $10.65+3.80%
- $204.97+2.59%
- Market cap
- $659.5M
- $42.84B
- 1M return
- +47.47%
- -4.74%
- 1Y return
- -19.46%
- +344.86%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 4
- 19
- Recent ratings
- 18
- 25
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest DNA
- Director Henry Christian O sold $35,405 worth of shares (5,000 units at $7.08), decreasing direct ownership by 21% to 19,310 units (SEC Form 4)
- Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
- SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
- Officer Coen Steven P. converted options into 743 shares and sold $2,302 worth of shares (330 units at $6.98), increasing direct ownership by 0.80% to 51,851 units (SEC Form 4) (tax liability)
- Ginkgo Bioworks downgraded by TD Cowen with a new price target
- SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 4 filed by Large owner Canton Barry
- SEC Form 4 filed by Officer Shetty Reshma P.
Latest RVMD
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)
- Goldman resumed coverage on Revolution Medicines with a new price target
- Officer Mancini Anthony sold $347,402 worth of shares (1,764 units at $196.94) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 40,352 units (SEC Form 4)
- Chief Development Officer Sandler Alan B. sold $67,941 worth of shares (341 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 52,868 units (SEC Form 4) to satisfy withholding tax
- Officer Mancini Anthony sold $353,449 worth of shares (1,774 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 42,116 units (SEC Form 4) (for tax liability)
- Officer Kelsey Stephen Michael sold $1,109,554 worth of shares (5,569 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 286,307 units (SEC Form 4) to satisfy withholding obligation
- Chief Operating Officer Horn Margaret A sold $989,613 worth of shares (4,967 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 149,680 units (SEC Form 4) (withholding tax)
- Officer Goldsmith Mark A sold $2,786,938 worth of shares (13,988 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 253,342 units (SEC Form 4) (for withholding tax)
- SVP & General Counsel Cislini Jeff sold $670,631 worth of shares (3,366 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 52,541 units (SEC Form 4) (tax liability)
- Chief Financial Officer Anders Jack sold $807,513 worth of shares (4,053 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 119,216 units (SEC Form 4) to satisfy withholding obligation